ziprasidone has been researched along with Carcinoma, Pancreatic Ductal in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Gu, X; Han, F; Li, H; Li, M; Shang, L; Yang, Y; Zheng, M | 1 |
1 other study(ies) available for ziprasidone and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Ziprasidone suppresses pancreatic adenocarcinoma cell proliferation by targeting GOT1 to trigger glutamine metabolism reprogramming.
Topics: Adenocarcinoma; Aspartate Aminotransferase, Cytoplasmic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Glutamine; Humans; Pancreatic Neoplasms; Piperazines; Thiazoles | 2022 |